The promise of CRISPR-based therapies hinges on the precision, purity, and performance of guide RNAs (gRNAs). Low-quality or impure gRNAs can reduce editing accuracy, increase off-target effects, and undermine the success of cell and gene therapies. As programs progress toward clinical translation, maintaining gRNA quality becomes even more critical. Ensuring gRNA quality across research, preclinical, and GMP stages demands tight process control, validated analytical methods, and adherence to regulatory expectations. Gaps in any of these areas can lead to product inconsistency and increased clinical risk. In this evolving landscape, choosing the right gRNA supplier is a critical step toward ensuring clinical success.

TriLink BioTechnologies invites you to learn from two experts helping to shape the future of CRISPR-based therapeutics. Dr. Cody Palumbo brings extensive experience in CRISPR development from the biotech and pharma industries, while Dr. Ortega leads analytical innovation for complex RNA products.

• In this session, they’ll explore how you can:
• Improve lead identification using high-purity gRNAs
• Apply advanced methods to verify gRNA quality
• Prepare your workflows for GMP manufacturing

Don’t miss this opportunity to level up your CRISPR programs with expert insights and practical takeaways. Register now to secure your spot and take the next step toward confident, clinic-ready gene editing.

Learning Objective 1 Understand how screening and lead candidate selection are enhanced with high-purity gRNAs
Learning Objective 2 Identify methods to ensure gRNA quality with advanced analytical characterization
Learning Objective 3 Gain practical insights to de-risk and simplify the transition to GMP manufacturing
Learning Objective 4 Explore comprehensive gene editing solutions from TriLink